Compare GSK plc (GSK) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Wells Fargo & Co — how do they compare? GSK plc trades at $52.33 (market cap $101.34B), while Wells Fargo & Co trades at $88.16 (market cap $265.03B). The key difference: Wells Fargo & Co is far larger — about 2.6× GSK plc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | WFC | |
|---|---|---|
Market Cap | $101.34B | $265.03B |
Sector | Health | Financials |
52-Week High | $61.18 | $96.40 |
52-Week Low | $36.20 | $73.42 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Wells Fargo (WFC) stock trades at $85.525, down 2.48% on the day, following a strong Q2 2026 earnings beat where EPS of $1.96 exceeded the $1.73 estimate. The technical outlook is bullish with price near the pivot point of $86, while fundamentals show improving profitability with a 25.97% net income margin. Analyst sentiment remains positive with a $97.36 consensus price target, though recent cash flow trends show operational challenges.
The outlook for WFC is cautiously optimistic with growth initiatives in wealth management and investment banking driving revenue. Key risks include net interest margin pressure and volatile cash flows, while the 12.72 P/E ratio offers reasonable valuation. Upside potential exists toward the $97.36 analyst target if earnings momentum continues post-asset cap removal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
